Clinical Scorecard: B-Cell Subset Analysis as a Predictor of Vaccine Response to SARS-CoV-2 in Recipients of Solid Organ Transplants
At a Glance
Category
Detail
Condition
Impaired humoral immunity in solid organ transplant recipients (SOTRs) under chronic immunosuppression
Key Mechanisms
Altered B-cell subset distributions correlate with SARS-CoV-2 vaccine antibody responses; reduced clonal diversity and maturation of vaccine-specific B cells
Target Population
Adult recipients of solid organ transplants (kidney, liver, heart, lung, multiorgan) receiving SARS-CoV-2 mRNA vaccines
Care Setting
Transplant outpatient clinics and immunocompromised patient monitoring settings
Key Highlights
Three distinct B-cell compartment groups identified in SOTRs correlate with SARS-CoV-2 vaccine serologic responses.
Group 1: Naive-dominant B-cell pool with vaccine responses similar to healthy controls; Group 2: Reduced naive but expanded memory B cells with variable responses; Group 3: Lymphopenia and poor vaccine responses.
Even SOTRs with strong immune responses show reduced B-cell clonal diversity and maturation compared to healthy controls.
Guideline-Based Recommendations
Diagnosis
Evaluate circulating B-cell subsets (naive, memory, total counts) to stratify immune competence in SOTRs.
Use SARS-CoV-2 vaccine-specific IgG antibody titers as a functional correlate of humoral immunity.
Management
Consider B-cell subset profiling to inform risk stratification and guide immunosuppressive therapy adjustments.
Non-live vaccines like SARS-CoV-2 mRNA vaccines are generally safe and recommended in SOTRs.
Multiple vaccine doses may be necessary to achieve detectable antibody responses in SOTRs.
Monitoring & Follow-up
Monitor B-cell subset distributions longitudinally to assess immune competence and vaccine responsiveness.
Assess antibody titers approximately 4 weeks postvaccination, noting possible delays in SOTRs.
Risks
Chronic immunosuppression increases infection risk and impairs vaccine responses.
Vaccination may theoretically stimulate allogenic responses but non-live vaccines are considered safe.
Patient & Prescribing Data
Solid organ transplant recipients on chronic immunosuppressive therapy receiving SARS-CoV-2 mRNA vaccines
B-cell subset analysis can predict vaccine response variability; tailored vaccination schedules and immunosuppression management may improve outcomes.
Clinical Best Practices
Perform integrated B-cell phenotyping and serologic testing to evaluate immune competence in SOTRs.
Use SARS-CoV-2 vaccination as a model antigen to assess humoral immune function without confounding by immune memory.
Incorporate B-cell subset data into clinical decision-making for vaccination timing and immunosuppressive regimen adjustments.
by James J Knox, Ingi Lee, Emily A Blumberg, Aaron M Rosenfeld, Wenzhao Meng, Fang Liu, Charlotte Kearns, Una O’Doherty, Abraham Shaked, Kim M Olthoff, Eline T Luning Prak
